

Inpixon Reports Second Quarter 2022 Financial Results and Provides Business Update

Achieves 55% Increase in Revenue for Six Months Ended June 30, 2022 Versus Same Period Last Year

Conference Call to be Held Today at 4:30 p.m. Eastern Time

PALO ALTO, Calif., Aug. 15, 2022 /PRNewswire/ -- Inpixon® (Nasdaq: INPX), the Indoor Intelligence® company, today provided a business update and reported financial results for its 2022 second quarter ended June 30, 2022.



"We continued to show growth during the second quarter despite macroeconomic challenges, illustrated by achieving \$4.7 million in revenue for the three months and \$10.0 million for the six months ended June 30, 2022, a 37% and 55% increase, respectively, when compared to the prior year periods," commented Nadir Ali, CEO of Inpixon. "Notably, our revenue growth is shifting to more organic growth, and while we are adding new enterprise organizations to our customer base every quarter, we are also deepening our relationship with our existing customers with add-ons and new integrations after our initial deployment.

"We have designed our solutions and technologies to help organizations create and redefine exceptional workplace experiences that enable smarter, safer and more secure environments, while attaining higher levels of productivity, improved worker and employee satisfaction rates, and a more connected workplace. Due to our marketing and sales activities coupled with third-party recognition and awards, we continue to see top-tier organizations implementing our technologies into their organizations. Additionally, our enterprise apps recently received ISO/IEC certification, confirming our information security policies and processes meet stringent industry best practices and standards. As a result, we believe this and our other certifications will allow us to move through customer engagements and sign new contracts more swiftly.

"Furthermore, we recently joined SAP's partner program where we are able to market our smart factory, smart warehouse, and digital supply chain solutions to SAP's 440,000 customers through the SAP store. We believe this partner program will result in increased demand for our solutions, as well as increased exposure around the world.

"Overall, while we are cognizant of the macroeconomic challenges that may continue to lie ahead, we are focused on increasing efficiencies operationally, while also working to ensure that we continue to meet our growth goals," concluded Mr. Ali.

Financial Results

Revenues for the three and six months ended June 30, 2022, were \$4.7 million and \$10.0 million, respectively, compared to \$3.5 million and \$6.4 million for the comparable periods in the prior year for an increase of approximately 37% and 55%, respectively. This increase is primarily attributable to the increase in Indoor Intelligence sales, including our smart office app and real time location-based technologies as well as the addition of the Industrial IoT product line in the fourth quarter of 2021. Gross profit for the three and six months ended June 30, 2022, was \$3.3 million and \$7.2 million, respectively, compared to \$2.6 million and \$4.6 million for the 2021 respective periods, representing an increase of 30% and 55%, respectively. The gross profit margin for the three and six months ended June 30, 2022, was 70% and 72%, compared to 74% and 72% for the three and six months ended June 30, 2021, respectively. This decrease in margin is primarily due to the sales mix during the periods.

Net loss attributable to stockholders of Inpixon for the three and six months ended June 30, 2022, was \$19.9 million and \$31.1 million, respectively, compared to income of \$14.8 million and \$2.2 million, respectively, for the comparable periods in the prior year. This increase in loss was primarily attributable to non-cash items in the three months ended June 30, 2021 period including the discounted net gain on the Sysorex note and the release of the valuation allowance on the Sysorex note, offset by increased operating expenses in the three and six months ended June 30, 2022.

Non-GAAP Adjusted EBITDA for the three and six months ended June 30, 2022, was a loss of \$9.9 million and \$18.7 million, respectively, compared to a loss of \$6.3 million and \$11.8 million for the prior year periods, respectively. Non-GAAP Adjusted EBITDA is defined as net income or loss before interest, provision for income taxes, depreciation and amortization plus adjustments for other income or expense items, non-recurring items and non-cash items including stock-based compensation.

Proforma non-GAAP net loss per basic and diluted common share for the three and six months ended June 30, 2022, was a loss of \$0.07 per share and \$0.13 per share, respectively, compared to a loss of \$0.07 per share and \$0.14 per share for the prior year periods. Non-GAAP net loss per share is defined as net loss per basic and diluted share adjusted for non-cash items including stock-based compensation, amortization of intangibles and one-time charges and other adjustments including loss on the exchange of debt for equity, provision for valuation allowance on notes, and acquisition costs.

Conference Call

Inpixon management will host a conference call today at 4:30 p.m. Eastern Time to discuss

the company's financial results for the second quarter ended June 30, 2022, as well as to review the company's corporate progress and other developments.

The conference call will be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 618409. A webcast of the call may be accessed at

https://www.webcaster4.com/Webcast/Page/2235/46295 or on the company's Investor Relations section of the website, ir.inpixon.com.

Investors and other interested parties are invited to submit questions to management prior to the call's start via email to inpx@crescendo-ir.com.

A webcast replay will be available on the company's Investor Relations section of the website (<u>ir.inpixon.com</u>) through August 15, 2023. A telephone replay of the call will be available approximately one hour following the call, through August 22, 2022, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code 46295.

About Inpixon

Inpixon® (Nasdaq: INPX) is the innovator of Indoor Intelligence®, delivering actionable insights for people, places and things. Combining the power of mapping, positioning and analytics, Inpixon helps to create smarter, safer, and more secure environments. The company's Indoor Intelligence and mobile app solutions are leveraged by a multitude of industries to optimize operations, increase productivity, and enhance safety. Inpixon customers can take advantage of industry leading location awareness, RTLS, workplace and hybrid event solutions, analytics, sensor fusion, IIoT and the IoT to create exceptional experiences and to do good with indoor data. For the latest insights, follow Inpixon on LinkedIn, Twitter, and visit inpixon.com.

Safe Harbor Statement

All statements in this release that are not based on historical fact are "forward-looking" statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Inpixon and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of economic conditions, the impact of COVID-19, global conflicts, inflation and other global events on Inpixon's results of operations and global supply chain constraints, Inpixon's ability to integrate the products and business from recent acquisitions into its existing business, the performance of management and employees, the regulatory landscape as it relates to privacy regulations and their applicability to Inpixon's technology, Inpixon's ability to maintain compliance with Nasdag's minimum bid price requirement and other continued listing requirements, the ability to obtain financing if needed, competition, general economic conditions and other factors that are detailed in Inpixon's periodic and current reports available for review at sec.gov. Furthermore, Inpixon operates in a highly

competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Inpixon disclaims any intention to, and undertakes no obligation to, update or revise forward-looking statements.

Non-GAAP Financial Measures

Management believes that certain financial measures not in accordance with generally accepted accounting principles in the United States ("GAAP") are useful measures of operations. EBIDTA, Adjusted EBITDA and pro forma net loss per share are non-GAAP measures. Inpixon defines "EBITDA" as net income (loss) before interest, provision for (benefit from) income taxes, and depreciation and amortization. Management uses Adjusted EBITDA as a metric for which it manages the business, and Inpixon defines "Adjusted EBITDA" as EBITDA plus adjustments for other income or expense items, non-recurring items and non-cash items. Inpixon defines "pro forma net loss per share" as GAAP net loss per share adjusted for stock-based compensation, amortization of intangibles and one-time charges including loss on the exchange of debt for equity and provision for valuation allowances.

Management provides Adjusted EBITDA and pro forma net loss per share measures so that investors will have the same financial information that management uses, which may assist investors in assessing Inpixon's performance on a period-over-period basis. Adjusted EBITDA or pro forma net loss per share is not a measure of financial performance under GAAP, and should not be considered an alternative to net income (loss) or any other measure of performance under GAAP, or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA and pro forma net loss per share have limitations as analytical tools and should not be considered either in isolation or as a substitute for analysis of Inpixon's results as reported under GAAP.

For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please see the "Reconciliation of Non-GAAP Financial Measures" table accompanying this press release.

Inpixon Contacts

General inquiries:

Inpixon

Email: marketing@inpixon.com Web: inpixon.com

Investor relations:

Crescendo Communications, LLC

Tel: +1 212-671-1020

Email: INPX@crescendo-ir.com

INPIXON AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except number of shares and par value data)

As	of
June 30,	December 31,
2022	2021
(Unaudited)	(Audited)

Accounts receivable, ent of allowances of \$268 and \$272, respectively 2,767 3,218 1 321 1 141 141 141 141 141 141 141 141 141		\$	65,755	\$	52,480
Other receivables 311 321 Inventory, net realizable value 1,581 1,766 Short-term investments - 43,125 Note receivable 5,67 - Prepaid assets and other current assets 79,844 105,962 Property and equipment, net 1,348 1,442 Operating lease right-of-use asset, net 1,582 1,736 Software development costs, net 1,647 1,792 Investment in Equity Securities 582 1,838 Cong-term investments 2,500 2,500 Intangible assets, net 30,126 33,478 Goodwill - 7,672 Other assets 217 263 Total Assets \$117,846 \$156,673 LIABILITIES AND STOCKHOLDERS' EQUITY Euronet Liabilities \$1,166 \$156,673 Current Liabilities \$900 \$2,414 Accounts payable \$900 \$2,414 Accounts payable \$900 \$2,414 Accounts payable \$900 \$2,414 Accounts payable		Ψ		Ψ	•
Inventory, net realizable value			,		
Short-term investments - 43,125 Note receivable 5,967 - Prepaid assets and other current assets 78,844 105,962 Property and equipment, net 1,348 1,442 Operating lease right-of-use asset, net 1,582 1,736 Software development costs, net 1,687 1,792 Investment in Equity Securities 552 1,838 Long-term investments 2,500 2,500 Indaplible assets, net 30,126 33,478 Goodwill - - 7,672 Other assets 217 253 Total Assets \$117,846 \$156,673 LIABILITIES AND STOCKHOLDERS' EQUITY *** *** Current Liabilities \$900 \$2,414 Accounts payable \$900 \$2,414 Accourable passe obligation, current 600 643 Deferred revenue 3,633 4,805 Short-term debt 1,911 3,490 Acquisition liability 1,02 1,108 Othe	Inventory, net realizable value				
Note receivable Prepaid assets and other current assets 3,463 4,42 Total Current Assets 79,844 105,962 Property and equipment, net 1,348 1,442 Operating lease right-of-use asset, net 1,647 1,792 Investment in Equity Securities 52,2500 2,500 Interpret investments 2,500 2,500 Interpret investments 30,162 33,478 Coordwill 1,772 1,772 Coordwill 1,772 1,772 Courter Assets 2,17 2,500 Courter Liabilities 2,000 2,500 Current Liabilities 3,000 2,241 Accrued liabilities 5,000 6,43 Courter Accrued liabilities 3,000 6,43 Courter Accrued liabilities 3,000 6,43 Courter Accrued liabilities 3,000 6,43 Courter Acquestion liability 3,486 5,114 Total Current Liabilities 1,000 6,43 Courter Acquestion liability 3,480 5,114 Total Current Liabilities 1,000 1,000 Courter Acquestion liability 3,480 5,114 Total Current Liabilities 1,000 1,000 Courter Acquestion liability 3,480 5,114 Total Current Liabilities 1,000 1,000 Courter Acquestion liability 3,480 5,114 Total Current Liabilities 1,000 1,000 Courter Acquestion liability 3,480 5,114 Total Liabilities 2,000 2,000 Courter Acquestion liability 3,480 5,114 Total Liabilities 2,000 2,000 Courter Acquestion liability 3,480 5,114 Total Liabilities 2,000 2,000 Courter Acquestion liability 3,480 5,114 Total Liabilities 2,000 2,000 Courter Acquestion liability 3,480 5,114 Total Liabilities 3,145 5,000 Courter Acquestion liability 3,480 5,114 Courter Acquestion liability 3,000 Courter Acquestion liability 3,000 Courter Acquestion liability 3,000 Courter Acquestion liability 3,000 Courter Acquestion liability			´ -		
Total Current Assets 79,844 105,962			5,967		· -
Property and equipment, net	Prepaid assets and other current assets		3,463		4,842
Depart in please right-of-use asset, net 1,882 1,736 55thware development costs, net 1,647 1,792 1,792 1,792 1,893 1,838	Total Current Assets		79,844		105,962
Software development costs, net investment is Equity Securities 1,647 1,792 Investment is Equity Securities 582 1,838 Long-term investments 2,500 2,500 Islandiplie assets, net 30,126 33,478 Goodwill 2,7672 253 Other assets 217 253 Total Assets 3,178 5,117,846 \$156,673 LIABILITIES AND STOCKHOLDERS' EQUITY 4,116 10,665 6,667 Accounts payable \$900 2,414 Accounts payable 4,116 10,665 Accounts payable \$900 2,414 Accounts payable 4,116 10,665 Accounts payable \$900 3,438 4,805 5,141 10,665 Accounts payable \$900 3,438 4,805 5,141 1,966 Accounts payable \$900 \$1,416 10,665 1,966 1,966 1,966 1,966 1,966 1,966 1,966 1,966 1,966 1,966 1,966 1,966 1,966 1,966 <td></td> <td></td> <td></td> <td></td> <td></td>					
Investment Equity Securities 582 1.838					,
					,
Mangible assets, net					
Constraint Con	· ·				
Diter assets 217 253 251 253 251 253 251 253 251 253 251 253 251 253 251 253 251 251 253 251 2			30,126		
			- 247		
LiaBilITIES AND STOCKHOLDERS' EQUITY Courrent Liabilities		•		Φ.	
Accounts payable	Total Assets	<u> </u>	117,846	<u> </u>	100,073
Accurued liabilities	•				
Accrued liabilities		Φ	000	Ф	2 444
Operating lease obligation, current 600 643 Deferred revenue 3,638 4,805 Short-term debt 1,911 3,490 Acquisition liability 3,486 5,114 Total Current Liabilities 1,022 1,108 Operating lease obligations, noncurrent 28 28 Operating lease obligations, noncurrent 28 28 Acquisition liability, noncurrent 15,701 28,487 Commitments and Contingencies - - 220 Commitments and Contingencies - - - - Mezzanine Equity Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. - 44,695 Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; saries and susceptively. - 44,695 Stockholders' Equity - 48,158 - Stockholders' Equity - - - Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; 1sisued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; - - <td< td=""><td>1 7</td><td>Ф</td><td></td><td>Ф</td><td></td></td<>	1 7	Ф		Ф	
Deferred revenue					
Short-term debt					
Acquisition liabilities					,
Total Current Liabilities					
Operating lease obligations, noncurrent 1,022 1,108 Other liabilities, noncurrent 28 28 Acquisition liability, noncurrent 15,701 28,487 Total Liabilities 15,701 28,487 Commitments and Contingencies - - Mezzanine Equity - - Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. - 44,695 Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 33,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) 48,158 - Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively;				-	
Operating lease obligations, noncurrent 1,022 1,108 Other liabilities, noncurrent 28 28 Acquisition liability, noncurrent 15,701 28,487 Total Liabilities 15,701 28,487 Commitments and Contingencies - - Mezzanine Equity - - Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. - 44,695 Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 33,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) 48,158 - Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively;	L T L. L. 1965				
Acquisition liability, noncurrent 28 28 220			4.000		4.400
Acquisition liability, noncurrent Total Liabilities 15,701 28,487					,
Acquisition liability, noncurrent Total Liabilities 15,701 28,487 28,487 Total Liabilities	Other liabilities, noncurrent				
Mezzanine Equity Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 10,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. 30, 2022 and December 31, 2021, respectively. 3155 124 Additional paid-in capital Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon Non-controlling interest Total Stockholders' Equity					
Mezzanine Equity Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. 155 124 Additional paid-in capital 334,436 332,639 Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688	Total Liabilities		15,701		28,487
Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively 155 124 Additional paid-in capital 334,436 332,639 Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688	Commitments and Contingencies				
issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) **Stockholders' Equity** Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital Treasury stock, at cost, 1 share (695) Accumulated other comprehensive income Accumulated deficit (281,463) Stockholders' Equity Attributable to Inpixon Non-controlling interest 53,987 83,491 **Total Stockholders' Equity**					
Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) 48,158 — Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; — — — Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. — — — — Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. — 155 124 Additional paid-in capital 334,436 332,639 (695) (695) (695) Accumulated other comprehensive income 598 44 Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688					
and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital Treasury stock, at cost, 1 share Accumulated other comprehensive income Accumulated other comprehensive income Stockholders' Equity Attributable to Inpixon Non-controlling interest Total Stockholders' Equity Stockholders' Equity 48,158 48,158 48,158 48,158 48,158 48,158 48,158 48,158 48,158 48,158 48,158 48,158 48,158 48,158	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250				
Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. 155	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized;				44,695
Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital Treasury stock, at cost, 1 share Accumulated other comprehensive income Accumulated other comprehensive income Accumulated deficit Stockholders' Equity Attributable to Inpixon Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234				44,695
Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital Treasury stock, at cost, 1 share Accumulated other comprehensive income Accumulated other comprehensive income Accumulated deficit Stockholders' Equity Attributable to Inpixon Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021,		 48,158		44,695
Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. 155 124 Additional paid-in capital 334,436 332,639 Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723)		 48,158		44,695
Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. - - - Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. 155 124 Additional paid-in capital 334,436 332,639 Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity		 48,158		44,695
126 outstanding as of June 30, 2022 and December 31, 2021, respectively. - - - Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. 155 124 Additional paid-in capital 334,436 332,639 Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1		 48,158		44,695
Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. 155 124 30, 2022 and December 31, 2021, respectively. 334,436 332,639 Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively;		 48,158		44,695
and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital 334,436 332,639 Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and		 48,158 		44,695
30, 2022 and December 31, 2021, respectively. 155 124 Additional paid-in capital 334,436 332,639 Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively.		 48,158 		44,695
Additional paid-in capital 334,436 332,639 Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962		 48,158 		44,695
Treasury stock, at cost, 1 share (695) (695) Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June		- -		
Accumulated other comprehensive income 598 44 Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively.		155		 124
Accumulated deficit (281,463) (250,309) Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital		 155 334,436		 124 332,639
Stockholders' Equity Attributable to Inpixon 53,031 81,803 Non-controlling interest 956 1,688 Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital Treasury stock, at cost, 1 share		 155 334,436 (695)		 124 332,639 (695)
Total Stockholders' Equity 53,987 83,491	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital Treasury stock, at cost, 1 share Accumulated other comprehensive income		155 334,436 (695) 598		 124 332,639 (695) 44
	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital Treasury stock, at cost, 1 share Accumulated other comprehensive income Accumulated deficit		155 334,436 (695) 598 (281,463)		 124 332,639 (695) 44 (250,309)
	Series 7 Convertible Preferred Stock - 58,750 shares authorized; zero and 49,250 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital Treasury stock, at cost, 1 share Accumulated other comprehensive income Accumulated deficit Stockholders' Equity Attributable to Inpixon		155 334,436 (695) 598 (281,463) 53,031		 124 332,639 (695) 44 (250,309) 81,803
	issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. Series 8 Convertible Preferred Stock - 53,197.7234 shares authorized; 53,197.7234 and zero issued and outstanding as of June 30, 2022 and December 31, 2021, respectively. (Liquidation preference of \$53,197,723) Stockholders' Equity Preferred Stock - \$0.001 par value; 5,000,000 shares authorized; Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2022 and December 31, 2021, respectively; Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2022 and December 31, 2021, respectively. Common Stock - \$0.001 par value; 2,000,000,000 shares authorized; 155,105,962 and 124,440,924 issued and 155,105,961 and 124,440,923 outstanding as of June 30, 2022 and December 31, 2021, respectively. Additional paid-in capital Treasury stock, at cost, 1 share Accumulated other comprehensive income Accumulated deficit Stockholders' Equity Attributable to Inpixon Non-controlling interest		155 334,436 (695) 598 (281,463) 53,031		 124 332,639 (695) 44 (250,309) 81,803 1,688

INPIXON AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except per share data)

	For the Three Months Ended, June 30, 2022 2021				For the Si),	
	-	2022 (Unau	ıdit			2022 (Unau	dite	2021 ed)
		(Onac		.00)		(Onaa	u	, ,
Revenues Cost of Revenues	\$	4,725 1,396	\$	3,453 896	\$	9,956 2,782	\$	6,407 1,780
Gross Profit		3,329		2,557		7,174		4,627
Operating Expenses								
Research and development		4,912		3,223		8,997		5,931
Sales and marketing		2,324		2,073		4,600		3,712
General and administrative		6,897 147		8,828 535		13,002		17,999
Acquisition related costs Impairment of goodwill		7,570		555		268 7,570		1,005
Amortization of intangibles		1,369		1,191		2,691		1,693
Total Operating Expenses		23,219	_	15,850		37,128	_	30,340
							-	
Loss from Operations		(19,890)		(13,293)		(29,954)		(25,713)
Other Income (Expense) Interest income/(expense), net		176		1,555		178		1,206
Loss on exchange of debt for equity				1,555		176		(30)
Recovery of valuation allowance on related party loan -								(00)
held for sale				7,462				7,345
Other (expense)/income, net		(879)		125		(771)		511
Gain on related party loan - held for sale				49,817				49,817
Unrealized gain/(loss) on equity securities		247		(28,965)		(1,256)		(28,965)
Total Other Income (Expense)		(456)		29,994		(1,849)		29,884
Net Loss (Income), before tax		(20,346)		16,701		(31,803)		4,171
Income tax benefit/(provision)		16		(2,195)		(84)		(2,204)
Net (Loss) Income		(20,330)		14,506		(31,887)		1,967
Net (Loss) Income Attributable to Non-controlling Interest		(458)		(253)		(804)		(235)
Net Loss Attributable to Stockholders of Inpixon	\$	(19,872)	\$	14,759	\$	(31,083)	\$	2,202
Accretion of Series 7 preferred stock Accretion of Series 8 Preferred Stock		(6,237)				(4,555) (6,785)		
Deemed dividend for the modification related to Series 8 Preferred Stock						(2,627)		
Deemed contribution for the modification related to Warrants issued in connection with Series 8 Preferred								
Stock Amortization premium- modification related to Series 8						1,469		
Prefered Stock		1,252				1,362		
Net Loss (Income) Attributable to Common Stockholders	\$	(24,857)	\$	14,759	\$	(42,219)	\$	2,202
Net Loss Per Share - Basic Net Loss Per Share - Diluted	\$ \$	(0.16) (0.16)		0.13 0.13	\$ \$	(0.29) (0.29)		0.02 0.02
Weighted Average Shares Outstanding Basic Diluted		153,519,283 153,519,283		110,040,532 110,041,378		146,052,371 146,052,371		94,577,520 94,591,619
Comprehensive Loss Net Loss Unrealized gain on available for sale debt securities Unrealized foreign exchange loss from cumulative	\$	(20,330) 375	\$	14,506 	\$	(31,887) 375	\$	1,967
translation adjustments		282	_	52		180	_	(619)
Comprehensive Loss	\$	(19,673)	\$	14,558	\$	(31,332)	\$	1,348

INPIXON AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)

		For the Six Months Ended, June 30,		
		2022	e 50	2021
Cook Floure Hood in Operating Activities		(Unau	ıdite	d)
Cash Flows Used In Operating Activities Net loss	\$	(31,887)	\$	1,967
Adjustments to reconcile net loss to net cash used in operating activities:	•	(- , ,	·	,
Depreciation and amortization		650		625
Amortization of intangible assets		3,026		2,007 370
Amortization of right of use asset Stock based compensation		353 2,274		7,149
Earnout expense valuation benefit		(2,827)		
Loss on exchange of debt for equity				30
Amortization of debt discount				224
Amortization of original issued discount		(92)		(4.007)
Accrued interest income, related party Unrealized gain on note		344		(1,627) (490)
Recovery for valuation allowance held for sale loan		344		(7,345)
Gain on settlement of related party promissory note and loan related party receivable				(49,817)
		(1)		(4,507)
Deferred income tax		4.050		00.005
Unrealized loss on equity securities Impairment of goodwill		1,256 7,570		28,965
Other		181		 57
				٠.
Changes in operating assets and liabilities:				
Accounts receivable and other receivables		361		532
Inventory		285		(555)
Prepaid expenses and other current assets Other assets		1,357 25		(319) 203
Accounts payable		(1,498)		(331)
Accrued liabilities		542		2,494
Income tax liabilities		(40)		6,711
Deferred revenue		(1,096)		(238)
Operating lease obligation		(327)		(364)
Other liabilities Net Cash Used in Operating Activities	\$	(19,544)	\$	96 (14,163)
not out a cook in operating rounties	Ψ	(10,011)	Ψ	(11,100)
Cash Flows Used in Investing Activities				
Purchase of property and equipment		(140)		(149)
Investment in capitalized software Investments in short term investments		(306)		(373)
Purchase of convertible note		(5,500)		(2,000)
Purchases of treasury bills		(0,000)		(63,362)
Sales of treasury bills		43,001		28,000
Purchase of Systat licensing agreement				(900)
Acquisition of Game Your Game				184
Acquisition of CXApp				(15,186)
Acquisition of Visualix Net Cash Provided By (Used in) Investing Activities	\$	37,055	\$	(61) (53,847)
not out it formed by (occur iii) investing Addivides	Ψ	07,000	Ψ	(00,047)
Cash From Financing Activities				
Net proceeds from issuance of preferred stock and warrants	\$	46,906	\$	
Net proceeds from issuance of common stock and warrants				77,853
Net proceeds from promissory note Cash paid for redemption of preferred stock series 7		364 (49,250)		
Taxes paid related to net share settlement of restricted stock units		(336)		(1,687)
Loans to related party				(1,007)
Repayment of CXApp acquisition liability		(1,847)		(137)
Repayment of acquisition liability to Nanotron shareholders				(467)
Repayment of acquisition liability to Locality shareholders	Ф.		_	(500)
Net Cash (Used In) Provided By Financing Activities	\$	(4,163)	\$	74,945

Effect of Foreign Exchange Rate on Changes on Cash	(73)	(19)
Net Increase in Cash and Cash Equivalents	13,275	6,916
Cash and Cash Equivalents - Beginning of period	 52,480	 17,996
Cash and Cash Equivalents - End of period	\$ 65,755	\$ 24,912

Reconciliation of Non-GAAP Financial Measures:

	For the Three Mo		For the Six Months Ended, June 30,		
(In thousands)	2022	2021	2022	2021	
Net loss (income) attributable to common stockholders Adjustments:	(24,857)	14,759	(42,219)	2,202	
Non-recurring one-time charges:					
Loss on exchange of debt for equity	-	-	-	30	
Provision for valuation allowance on held for sale loan	-	(7,462)	-	(7,345)	
Gain on related party loan held for sale	-	(49,817)	-	(49,817)	
Unrealized loss on equity securities	(247)	28,965	1,256	28,965	
Acquisition transaction/financing costs	147	535	268	1,005	
Earnout compensation expense/(benefit)	-	2,059	(2,827)	2,059	
Accretion of series 7 preferred stock	-	· -	¥,555	-	
Accretion of series 8 preferred stock	6,237	_	6,785	-	
Deemed dividend for the modification related to Series 8 Preferred	,		,		
Stock	-	-	2,627	-	
Deemed contribution for the modification related to warrants issued					
in connection with Series 8 Preferred Stock Amortization premium- modification related to Series 8 Preferred	-	-	(1,469)	-	
Stock	(1,252)	_	(1,362)	_	
Professional service fees	(1,202)	422	(1,502)	771	
Impairment of goodwill	7,570	722	7,570		
impairment of goodwiii	35	(128)	124	(491)	
Unrealized losses/(gains) on notes, loans, investments	33	(120)	124	(431)	
Stock-based compensation – compensation and related					
benefits	741	2,053	2,274	7,149	
Severance costs	10	_,	121	-	
Interest (income)/expense, net	(176)	(1,555)	(178)	(1,206)	
Income tax benefit/(provision)	(16)	2,195	84	2,204	
Depreciation and amortization	1.870	1,695	3.676	2,638	
		.,	\$	\$	
Adjusted EBITDA	(9,938)	(6,279)	(18,707)	(11,836)	
	- 4	-	.		
	For the Three Mo		For the Six Mo		
(In the county of a county of any date)	June 30	,	June	,	
(In thousands, except share data)	2022	2021	2022	2021	
			\$	\$	

	June 30		June	
(In thousands, except share data)	2022	2021	2022	2021
			\$	\$
Net loss (income) attributable to common stockholders	(24,857)	14,759	(42,219)	2,202
Adjustments:				
Non-recurring one-time charges:				
Loss on exchange of debt for equity	-	-	-	30
Provision for valuation allowance on held for sale loan	-	(7,462)	-	(7,345)
Gain on related party loan held for sale	-	(49,817)	-	(49,817)
Unrealized loss on equity securities	(247)	28,965	1,256	28,965
Acquisition transaction/financing costs	`147 [´]	535	268	1,005
Earnout compensation expense/(benefit)	-	2,059	(2,827)	2,059
Accretion of series 7 preferred stock	-	-	4,555	-
Accretion of series 8 preferred stock	6,237	-	6,785	-

Preferred Stock 2,627 Deemed contribution for the modification related to	-
Deemed contribution for the modification related to	-
warrants issued	-
in connection with Series 8 Preferred Stock (1,469)	
Amortization premium- modification related to Series 8 Preferred	
Stock (1,252) - (1,362)	-
Professional service fees - 422 8 7	771
Impairment of goodwill 7,570 - 7,570	-
Unrealized losses/(gains) on notes, loans, investments 35 (128) 124 (49)	491)
Stock-based compensation – compensation and related	
benefits 741 2,053 2,274 7,14	149
Severance costs 10 - 121	-
Amortization of intangibles 1,537 1,361 3,026 2,0	011
Proforma non-GAAP net loss (10,079) (7,253) (19,263) (13,46	461)
\$ \$ \$	
Proforma non-GAAP net loss per basic and diluted common share(0.07)(0.07)(0.13)(0.13)	1.14)
Weighted average basic and diluted common shares outstanding 153,519,283 110,040,532 146,052,371 94,577,52	520

SOURCE Inpixon

C View original content to download multimedia https://www.prnewswire.com/news-releases/inpixon-reports-second-quarter-2022-financial-results-and-provides-business-update-301605982.html